Pemetrexed is an antimetabolic agent and is well-known as a potent inhibitor of thymidylate synthase (TS). It also inhibits dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). We reported an intriguing case in which a non-small cell lung cancer patient who was refractory to pretreatment with S-1, a strong TS inhibitor, showed good response to pemetrexed treatment.
Introduction
Pemetrexed and S-1 are antitumor agents frequently used in patients with non-small cell lung cancer (NSCLC). The result of a phase III trial indicated the usefulness of pemetrexed as chemotherapy for patients with previously treated NSCLC [1] . Both of these are antimetabolic agents considered to inhibit mainlythymidylate synthase (TS). TS is essential for DNA synthesis and is one of the principal targets of anti-tumor treatment; however, a clear difference between these TS inhibitors has not been observed in clinical practice. We report an interesting case in which a NSCLC patient showed good response to pemetrexed even after progressive disease was observed following treatment with S-1.
Case Report
A 54-year-old woman presented with cough and sputum. Previously she had been diagnosed as having adenocarcinoma of the lung (cT4N3M0 stage IIIB) and received first-line chemotherapy with S-l (100 mg/body, d1-14) and cisplatin (80 mg/m 2 , d1) on a three-week schedule [2] . After two cycles of this treatment, the tumor showed progressive disease.
About a month later she enrolled in a clinical trial in which second-line chemotherapy was started with pemetrexed 500 mg/m 2 [3] [4]. The target lesion was located in the right upper lobe of the lung, and non-target lesions were observed in the left hilar lymph node, right hilar lymph node, and mediastinal lymph node. The patient also presented with lymphangitiscarcinomatosa (Figure 1(a) ). Although there was no tumor response with S-1 and cisplatin therapy, partial response (PR) was observed after three cycles of treatment with pemetrexd, and continued for three cycles with the largest decrease in tumor size (40.0 mm to 9.5 mm: 76.2% reduction) seen in the right upper lobe after four cycles, as shown in Figure 1(b) . After seven cycles, disease progression was observed and treatment was discontinued; progression-free survival (PFS) was 5.2 months. During this treatment, grade 3 neutropenia and leucopenia, which were possibly related to pemetrexed, were observed several times, but the patient recovered from all events. No serious adverse event was observed in this patient.
The patient was followed by other chemotherapies and died approximately 21 months after the first administration of pemetrexed.
Discussion
Single-agent chemotherapy with pemetrexed has been studied in previously treated patients in a Japanese phase II trial [3] [4] . Results from the randomized phase III trial showed a response rate of 9.1% and median progression-free survival of 2.9 months. In the randomized Japan phase II trial, patients previously treated for locally advanced or metastatic non-small cell lung cancer were assigned to receive pemetrexed 500 or 1000 mg/m 2 . Results showed a response rate of 18.5% (95% Confidence Interval [CI]: 12.6% -25.8%) with median progression-free survival of 3.0 months (95% CI, 2.0 -3.5 months) in the 500 mg/m 2 group. This case was one of the 108 patients who were evaluable for efficacy in the 500 mg/m 2 group of the phase II trial. She received seven cycles of pemetrexed treatment with severe adverse events. Even though this patient showed no response to previous treatment with S-1 plus cisplatin combination therapy, a remarkable response (76.2% tumor reduction and progression-free survival of 5.2 months) was seen following treatment with pemetrexed. We feel that this notable difference in efficacy may have been due to differences in the mechanism of action between pemetrexed and S-1.
Both pemetrexed and S-1 are categorized as antimetabolic agents and strongly inhibit TS. However, these agents interact with two different TS substrate binding sites: one for deoxyuridine monophosphate (dUMP) and the other for the folate (5,10-methylenetetrahydrofolate polyglutamate). S-1 has three components: 5-Fluorouracil (5-FU) prodrug tegafur; 5-chloro-2, 4-dihydroxypyridine; and potassium oxonate. The 5-FU component is phosphorylated to 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP), which reacts with reduced folate cofactors to form a ternary complex with TS via interaction with dUMP binding site, thereby inhibiting pyrimidine synthesis. In contrast, pemetrexed, which is rapidly metabolized to active polyglutamate derivatives within cells, has a structure similar to that of folate. Pemetrexed inhibits pyrimidine synthesis by binding to TS instead of folate. Consequently, the interaction with TS is substantially different from that of S-1. In addition, pemetrexed was shown to have a high inhibitory effect on dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT) as well as TS in a previous preclinical research. It was reported that the Ki value of pemetrexed pentaglutamates was 1.3 nM for TS inhibition, which may be comparable or superior to the reported Ki value of 6.4 nM for 5-FU. Furthermore, pemetrexed pentaglutamates have also shown strong inhibition of DHFR and GARFT. The in vitro study has obtained Ki values of 7.2 nM and 65 nM, respectively, for each of these enzymes [5] [6] . Pemetrexed is a tight-binding inhibitor of several folatedependent enzymes and, as a result, inhibit pyrimidine/purine synthesis.
These differences in the mode of action may explain the clinical efficacy seen in this case. The response in this patient suggests that pemetrexed has a unique mode of action and is a potent multi-target antifolate agent in NSCLC.
